Dr. Vinay Prasad, who heads the Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER), responsible for overseeing vaccines and biotech medications, will be concluding his tenure at the end of April. This was confirmed by FDA Commissioner Marty Makary on Friday. Prasad's leadership has frequently been a point of contention within the FDA, with various reports highlighting staff grievances concerning his management style. His exit follows the introduction of several new FDA policies, which were a central aspect of his work.
Dr. Vinay Prasad's departure from the FDA marks the end of a turbulent period characterized by several high-profile disputes. He initially joined the FDA after leaving the University of California, San Francisco, with an original plan to stay for the duration of his academic leave. However, his tenure was shortened, as noted by Commissioner Marty Makary to The Wall Street Journal. The division led by Prasad at the FDA is tasked with assessing a wide array of treatments, including oncological medicines, gene therapies, and immunizations.
A significant point of controversy during Prasad's time was his temporary removal from the agency, followed by his re-hiring in August 2025. This re-instatement occurred despite his history of advocating for more liberal policies, which had led to his earlier dismissal. His return ignited considerable debate regarding the FDA's future regulatory direction, especially given his outspoken critical stance on the biopharmaceutical sector and certain existing FDA approval processes.
Furthermore, Prasad's leadership was characterized by a more stringent and cautious approach to vaccine policy. He pushed for stricter approval criteria, referencing reported fatalities in children linked to COVID inoculations, which subsequently caused considerable unease within the industry. His decisions also included regulatory reversals for medications treating rare diseases and a notable refusal to consider a flu vaccine application from Moderna Inc. (NASDAQ: MRNA). These actions underscore the impact of his controversial tenure on both the FDA and the broader pharmaceutical landscape.
Dr. Vinay Prasad’s exit concludes a period marked by significant shifts and challenges within the FDA’s CBER, leaving a lasting impression on vaccine and biotech drug regulation.